Accelerating Drug Development and Manufacturing with Engineered Enzymes
In 2016, the (bio)pharmaceutical industry continues to face escalating demands to improve productivity, build pipelines faster, streamline infrastructure, reduce costs, and shorten time to market. At the same time, sponsor companies must meet increasingly rigorous regulatory expectations and conduct more complex clinical trials. Although the industry has traditionally been slow to embrace new processes and technologies, effective methods to accomplish these objectives are extremely valuable.
In this article, Codexis, Inc. highlights how technological advancements over the past decade have met many critical industry needs, and how long-held preconceptions about the use (and usefulness) of enzymes in the synthesis of APIs have been eroded.